CompletedPhase 4

Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients

Egypt250 participantsStarted 2023-08-01

Plain-language summary

* Study the effect of acetylcysteine on decreasing the incidence of LIT in critically ill patients. * Study the impact of acetylcysteine on the time to onset of LIT and the time to recovery of platelets.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients (age ≥ 18 years) * Admitted to the Intensive Care Unit (ICU) * Candidates for intravenous linezolid therapy for ≥ 48 hours Exclusion Criteria: * Baseline platelet count \< 50 × 10⁹/L * Diagnosis of malignancy * Receipt of any chemotherapeutic agent within the past 6 months * Positive COVID-19 RT-PCR test at admission * Diagnosis of immune thrombocytopenia * Presence of splenomegaly * Presence of liver cirrhosis * Presence of hepatitis C * Refusal to provide informed consent

What they're measuring

difference in incidence of LIT between patients who received NAC and patients who didn't.

Timeframe: From starting linezolid untill 14 days after linezolid discontinuation or ICU discharge whichever comes first.

Trial details

NCT IDNCT05944458

SponsorHelwan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Linezolid trials